Methylene Blue for Side Effects of Cancer Immunotherapy
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests if methylene blue can help people who develop side effects called CRS or ICANS after treatments like CAR-T cells or bispecific antibodies. It is a first-in-human study to find a safe dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer (like leukemia or lymphoma).
- You are 18 years or older.
- You received an immunotherapy (like CAR-T cells) and had side effects called CRS or ICANS (at least mild).
- Your heart function is normal (measured by an ultrasound).
- You are willing to use effective birth control if able to have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug, CTO1681, that may help prevent or treat cytokine release syndrome (CRS) — a common side effect of CAR T-cell therapy. It could make the recovery period safer and more comfortable.
This trial tests if the drug Siltuximab can help control side effects (CRS and ICANS) that sometimes happen after CAR-T treatment for multiple myeloma. It may help patients who develop these symptoms.
This trial tests a methylene blue gel for people with certain types of basal cell carcinoma (a common skin cancer) who cannot have surgery or radiation. The goal is to see if the gel can treat the cancer safely and effectively.
This trial tests a new methylene blue formula injected into skin cancer tumors that cannot be removed by surgery or treated with radiation. It is for people who have one or more small tumors (each less than 2 cm) and cannot have the usual treatments.
This trial tests a new way to give treatment directly into the spinal fluid for a serious side effect of CAR T cell therapy called ICANS. It may help people with certain types of lymphoma who are getting standard CAR T therapy and experience this brain-related complication.
This trial tests if a spinal injection of three common chemotherapy drugs can reduce or prevent serious brain and nerve side effects in people receiving CAR-T cell therapy for cancer.
Hear when a new Cytokine Release Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.